Cosmax Nbt, Inc. (KOSDAQ:222040)
South Korea
· Delayed Price · Currency is KRW 3,350.00
-65.00 (-1.90%)
At close: Mar 6, 2026
Cosmax Nbt Revenue
Cosmax Nbt had revenue of 65.67B KRW in the quarter ending September 30, 2025, a decrease of -23.47%. This brings the company's revenue in the last twelve months to 293.75B, down -7.62% year-over-year. In the year 2024, Cosmax Nbt had annual revenue of 317.99B, down -4.69%.
Revenue (ttm)
293.75B
Revenue Growth
-7.62%
P/S Ratio
0.23
Revenue / Employee
572.61M
Employees
513
Market Cap
66.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 317.99B | -15.65B | -4.69% |
| Dec 31, 2023 | 333.63B | 5.42B | 1.65% |
| Dec 31, 2022 | 328.21B | 38.86B | 13.43% |
| Dec 31, 2021 | 289.35B | 22.56B | 8.45% |
| Dec 31, 2020 | 266.79B | 72.52B | 37.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinil Pharmaceutical | 80.97B |
| Optipharm.CO.,LTD | 21.98B |
| Jin Yang Pharmaceutical | 117.19B |
| RP Bio | 134.21B |
| BL Pharmtech | 6.98B |
| Polaris AI Pharma | 63.94B |
| GL Pharm Tech | 34.30B |
| Hwail Pharmaceutical | 107.87B |